Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.
Pfizer's LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Community raises over $47,000 for Crow Wing County deputy brainerddispatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from brainerddispatch.com Daily Mail and Mail on Sunday newspapers.